Published in Cancer Cell on July 07, 2009
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia (2010) 1.71
mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev (2012) 1.33
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
Tumour suppressors: Different roads to inactivation. Nat Rev Cancer (2009) 1.13
SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell (2011) 1.13
NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res (2010) 1.08
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res (2012) 0.96
Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. J Biol Chem (2010) 0.96
p97-containing complexes in proliferation control and cancer: emerging culprits or guilt by association? Genes Cancer (2010) 0.96
The NF1 gene revisited - from bench to bedside. Oncotarget (2014) 0.91
miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget (2015) 0.91
Regulation of Ras proteins by reactive nitrogen species. Free Radic Biol Med (2011) 0.90
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res (2012) 0.89
Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells. Curr Opin Hematol (2010) 0.89
Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation. Mol Cell Biol (2011) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov (2014) 0.86
Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov (2013) 0.85
SPRED proteins provide a NF-ty link to Ras suppression. Genes Dev (2012) 0.84
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer (2016) 0.82
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget (2016) 0.81
Generation of cancerous neural stem cells forming glial tumor by oncogenic stimulation. Stem Cell Rev (2012) 0.80
Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol (2012) 0.80
Evidence for and against regional differences in neural stem and progenitor cells of the CNS. Genes Dev (2010) 0.79
Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. J Neuropathol Exp Neurol (2015) 0.78
Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells. Cell Cycle (2014) 0.77
Increased wild-type N-ras activation by neurofibromin down-regulation increases human neuroblastoma stem cell malignancy. Genes Cancer (2011) 0.76
Regulation of the viability of Nf1 deficient cells by PKC isoforms. Oncotarget (2014) 0.76
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys (2010) 0.76
A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. BMC Genomics (2017) 0.75
Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner. J Biol Chem (2016) 0.75
Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C. Oncotarget (2016) 0.75
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells. Phytochem Lett (2014) 0.75
Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth. J Nat Prod (2012) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
RAS Proteins and Their Regulators in Human Disease. Cell (2017) 0.75
Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes. Sci Rep (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell (1995) 21.15
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Stimulation of p21ras upon T-cell activation. Nature (1990) 5.72
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell (1990) 3.56
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20
Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. Anticancer Res (1996) 3.12
Senescence comes of age. Nat Med (2005) 2.39
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Targeting the protein kinase C family: are we there yet? Nat Rev Cancer (2007) 2.29
The sevenfold way of PKC regulation. Cell Signal (1998) 2.06
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science (1998) 2.06
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res (2005) 2.02
Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res (1994) 1.84
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery (1999) 1.52
Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol (2008) 1.41
Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer (2006) 1.41
Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat (2008) 1.30
Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 1.29
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 0.91
Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol (2007) 0.83
Molecular analysis at the NF1 locus in astrocytic brain tumors. Cancer (1995) 0.79
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell (2005) 11.19
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med (2010) 5.57
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity (2007) 4.74
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med (2005) 4.44
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07